Peptide for weight loss Which ones work? 2026 Guide
Semaglutide, tirzepatide, retatrutide, cagrilintide, brenipatide, AOD-9604: peptides studied for weight loss, ranked according to what studies actually show, with their mechanisms and status in 2026.
The peptides that have shown the greatest weight loss in studies act on satiety hormones: retatrutide (−24.2% in phase 2, not approved), tirzepatide (up to −22.5%, Mounjaro), the CagriSema combination (approximately −20%), and semaglutide (−14.9%, Wegovy). Other approaches (AOD-9604, MOTS-c, 5-Amino-1MQ) have yielded only modest results or have been observed in animal studies. In Europe, only semaglutide and tirzepatide are approved medications.
Introduction: Why peptides are at the heart of obesity research
Obesity is a complex disease involving hormonal, neuroendocrine, and metabolic dysregulations that go far beyond a simple calorie imbalance. Peptides—small signaling molecules naturally present in the body—act precisely on these dysregulations: regulation of appetite, lipid metabolism, energy expenditure, and insulin sensitivity.
Research into weight-loss peptides has accelerated dramatically since 2020, driven by the clinical successes of Semaglutide and Tirzepatide, which demonstrated that weight reductions of >15% were achievable pharmacologically. Retatrutide (>20%) and next-generation molecules are pushing these boundaries even further.
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are licensed, prescription medications. The other molecules in this guide are research compounds not approved as drugs. The information below is intended for laboratory researchers only.
Which peptide helps with weight loss? What studies show
Not all "slimming peptides" are created equal: some have clinical trials involving thousands of participants, while others have only results in mice. Classified by level of evidence:
- Large-scale clinical trials : semaglutide (−14.9%, STEP-1), tirzepatide (up to −22.5%, SURMOUNT-1), CagriSema (approximately −20%, REDEFINE 1) and retatrutide (−24.2% in phase 2, phase 3 TRIUMPH ongoing).
- Shorter or targeted trials : cagrilintide alone (−10.8% in 26 weeks, phase 2), tesamorelin (visceral fat), AOD-9604 (failure in phase 2b).
- Data primarily preclinical : MOTS-c, humanin, 5-Amino-1MQ, BPC-157.
In trials, the most effective weight-loss molecules have one thing in common: they act on satiety hormones (GLP-1, GIP, amylin), often on several at once. Other avenues remain the subject of ongoing research.
Retatrutide is often referred to as a "tripeptide weight loss" because it acts on three receptors. However, it is a single peptide, not a mixture of three: it is called a triple agonist.
Category 1 — Incretin agonists (GLP-1, GIP, Glucagon)
This is the most powerful and clinically documented family for body weight reduction.
Semaglutide — GLP-1 mono-agonist
Semaglutide (Ozempic, Wegovy) is a native GLP-1 analog with 94% homology, conjugated to a C18 diacid chain, which gives it a half-life of approximately 7 days (weekly administration). It reduces appetite primarily via GLP-1 receptors in the hypothalamus and slows gastric emptying.
- Average weight loss: -14.9% in 68 weeks (STEP-1 study, 2021)
- Improvement in blood sugar, lipids and blood pressure
- Tolerability: frequent nausea and vomiting during the titration phase
Tirzepatide — Dual GLP-1/GIP agonist
Tirzepatide (LY3298176, Mounjaro and Zepbound) is a dual GLP-1/GIP agonist developed by Eli Lilly. The addition of the GIP agonist potentiates the insulinotropic effect and improves insulin sensitivity in adipose tissue.
- Weight loss: -22.5% at a dose of 15 mg over 72 weeks (SURMOUNT-1)
- HbA1c reduction greater than insulin in T2DM studies
- FDA approval (Zepbound) for obesity in 2023
Retatrutide — GLP-1/GIP/Glucagon triple agonist
Retatrutide (LY3437943) represents the cutting edge of current research. The addition of glucagon agonism to the two aforementioned receptors increases basal energy expenditure and hepatic lipolysis—a fundamental mechanistic difference.
- Weight loss: -24.2% over 48 weeks at 12 mg (phase 2, NEJM 2023)
- Reduction of liver fat by -82% (MRI-PDFF)
- TRIUMPH Phase 3 Program in progress
→ Read the complete guide on Retatrutide
Brenipatide — monthly dual GIP/GLP-1 agonist
Brenipatide (LY3537031, Eli Lilly) activates the same receptors as tirzepatide, but it is designed for once-monthly administration. It is not primarily being studied for weight loss; its phase 3 program focuses on alcohol use disorder. It is of interest to research investigating the link between incretins and reward circuits.
→ Brenipatide Guide · Brenipatide 1 mg for research
Category 1 bis — Amylin analogues
Amylin is a hormone released with insulin after a meal. It enhances satiety through a different pathway than GLP-1, which explains the benefit of combining them.
Cagrilintide — a long-acting amylin analogue
Cagrilintide (Novo Nordisk) is an amylin analogue administered once weekly in trials. On its own, it reduced weight by 10.8% over 26 weeks in phase 2 (The Lancet, 2021).
- CagriSema : cagrilintide + semaglutide combination, approximately −20% in 68 weeks (REDEFINE 1 trial)
- Complementary mechanism of GLP-1: slowing of gastric emptying and satiety via the brainstem
→ Cagrilintide Guide · Retatrutide vs cagrilintide · Cagrilintide 5 mg for research
Category 2 — Growth hormone (GH) fragments
AOD-9604 — GH Fragment 176-191
AOD-9604 (Advanced Obesity Drug) is a synthetic fragment of amino acids 176-191 of human GH. Unlike complete GH, it has no effect on growth or blood glucose levels, but it is said to retain the lipolytic properties of GH.
Its supposed mechanism involves the activation of beta-3 adrenergic receptors in adipose tissue, stimulating lipolysis and inhibiting lipogenesis.
- Studies in rats and mouse models: significant reduction in fat mass
- Phase 2b clinical trials (2007): weight loss no superior to placebo, development stopped for obesity
- No effect on IGF-1 or blood glucose — favorable preclinical safety profile
- Used in research to understand GH-independent lipolytic pathways
Ipamorelin + CJC-1295 — GH Secretagogues
The combination Ipamorelin (selective ghrelin agonist) + CJC-1295 (GHRH analogue) stimulates the physiological secretion of GH by the pituitary gland. The released GH promotes lipolysis and the preservation of lean mass, particularly during calorie restriction.
- Particular interest in research on body composition (fat mass/lean mass ratio)
- Effect on visceral lipolysis > subcutaneous according to some studies
- No direct hypoglycemic effect (unlike insulin)
→ Read the CJC-1295 + Ipamorelin guide
Tesamorelin — GHRH analogue and visceral fat
Tesamorelin stimulates the secretion of growth hormone. It is one of the few peptides in this family that has been approved: it was approved in the United States in 2010 (Egrifta) for treating excess abdominal fat in patients living with HIV, with a reduction in visceral fat of approximately 15% in trials. It acts on fat distribution more than on total weight.
→ Tesamorelin: studies and status · Tesamorelin 10 mg for research
Category 3 — Hypothalamic-acting peptides
MOTS-c — Mitochondrial Peptide
MOTS-c is a mitochondrial genome peptide (12S rRNA), identified in 2015. Studies in mice show that it improves insulin sensitivity, reduces high-fat diet-induced obesity, and increases spontaneous physical activity.
- Mechanism: activation of the AMPK pathway in muscle and adipose tissue
- Reduction of insulin resistance in diabetic mouse models
- Few human studies to date — an emerging field
Humanin — Cytoprotective mitochondrial peptide
Humanin is another mitochondrial peptide that improves insulin sensitivity and reduces apoptosis in pancreatic islets. Preclinical studies suggest a role in the regulation of glucose and fat mass.
Category 4 — Peptides with indirect metabolic action
BPC-157 — Gastric Protection and Metabolism
BPC-157 (Body Protection Compound-157), primarily known for its effects on wound healing and gastric protection, also presents interesting data on lipid metabolism and regulation of the gut-brain axis in some preclinical models.
→ Read the complete BPC-157 guide
Two frequently cited molecules that are not peptides
Tesofensine — triple reuptake inhibitor
Tesofensine blocks the reuptake of serotonin, dopamine, and norepinephrine, thereby reducing food intake through a central action. Weight loss of 10% to 14% in phase 2. It is not a peptide but a small molecule; it is included here because it is often compared to peptides.
5-Amino-1MQ — NNMT inhibitor
5-Amino-1MQ blocks NNMT, an enzyme highly present in adipose tissue. In obese mice, it reduced fat mass without decreasing food intake. No clinical trials have been published to date. 5-Amino-1MQ 10 mg for research
Comparative table of peptides for weight loss
| Peptide | Primary target | Measured weight loss | Stadium | At MyPeptide |
|---|---|---|---|---|
| Retatrutide | GLP-1/GIP/glucagon | -24.2% (phase 2) | Phase 3 | View product |
| Tirzepatide | GLP-1/GIP | up to -22.5% | Authorized (Mounjaro) | View product |
| CagriSema | Amylin + GLP-1 | approximately -20% | Phase 3 | — |
| Semaglutide | GLP-1 | -14.9% | Authorized (Wegovy) | — |
| Cagrilintide | Amyline | -10.8% (26 weeks) | Phase 2-3 | View product |
| Brenipatide | GIP/GLP-1 | Unpublished | Phase 3 (alcohol) | View product |
| Tesamorelin | GHRH | Visceral fat ≈ −15% | Approved in the United States (HIV) | View product |
| CJC-1295 + Ipamorelin | GHRH/ghrelin | Body composition | Preclinical | — |
| AOD-9604 | Fragment of GH | Modest | Stopped after phase 2b | — |
| MOTS-c | mitochondrial AMPK | Mouse | Preclinical | View product |
Common characteristics of peptides that promote weight loss
Regardless of their specific mechanisms, the most effective peptides for body weight reduction in research share several characteristics:
- They act on several pathways simultaneously (multi-target > single-target)
- They preserve lean mass better than calorie-only approaches.
- Their side effects are primarily gastrointestinal and dose-dependent.
- A long duration of action (half-life > 24h) is associated with better efficacy
- Efficiency is generally dose-dependent with a plateau relationship
Frequently asked questions about peptides and weight loss
Which peptide is the most effective for weight loss?
In published trials, retatrutide, a triple GLP-1/GIP/glucagon agonist, achieved the greatest weight loss: −24.2% over 48 weeks in phase 2 (NEJM, 2023). This was followed by tirzepatide (up to −22.5% in SURMOUNT-1), the CagriSema combination (approximately −20%), and semaglutide (−14.9% in STEP-1). Retatrutide remains in phase 3 and is not approved.
Which weight loss peptides are authorized as medications?
In Europe, only semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are authorized, and only by prescription. Retatrutide, cagrilintide, brenipatide, MOTS-c, and AOD-9604 are research compounds not approved as medications.
What is the "tripeptide" for weight loss?
The word generally refers to retatrutide, so named because it acts on three receptors (GLP-1, GIP, and glucagon). However, it is a single peptide, not a chain of three. In biochemistry, a tripeptide is a chain of three amino acids, like GHK-Cu, regardless of weight.
What is the difference between retatrutide and tirzepatide?
Tirzepatide activates two receptors (GLP-1 and GIP) and is approved (Mounjaro). Retatrutide adds the glucagon receptor, which increases energy expenditure and fat burning in the liver: it performed better in phase 2 (−24.2% vs. −22.5%), but its phase 3 trials are ongoing.
Complete catalog of research peptides
MyPeptide offers retatrutide, tirzepatide, cagrilintide, brenipatide, tesamorelin, MOTS-c, and 5-Amino-1MQ for research, each with its own independent Janoshik analysis report. Shipping from the European Union in 2 to 5 business days.
- Semaglutide — Wilding JPH et al., STEP 1 trial, N Engl J Med, 2021.
- Tirzepatide — Jastreboff AM et al., SURMOUNT-1 trial, N Engl J Med, 2022.
- Retatrutide — Jastreboff AM et al., phase 2 trial, N Engl J Med, 2023 (PubMed 37366315).
- Cagrilintide — Lau DCW et al., phase 2 trial, The Lancet, 2021.
- CagriSema — Garvey WT et al., REDEFINE 1 trial, N Engl J Med, 2025.
- Tesamorelin — Falutz J et al., N Engl J Med, 2007.
📦 Retatrutide available for research in Europe
France · Belgium · Germany · Spain · Netherlands
And tesamorelin? It doesn't cause weight loss: it primarily reduces visceral fat, by about 15% over 26 weeks in trials. See tesamorelin and visceral fat and retatrutide vs tesamorelin.
And what about MOTS-c? This mitochondrial peptide affects glucose utilization by muscles rather than appetite. See MOTS-c and weight loss and our MOTS-c guide.

